Summary The objective of this observational study was to compare the efficacy of levetiracetam and topiramate during the first 15 days of add-on treatment in adults with refractory partial epilepsy.
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Two cohorts of patients with !3 simple or complex partial seizures with or without secondary generalisation per month over an 8-week baseline period received levetiracetam or topiramate in two distinct phases, in addition to standard antiepileptic treatment. During the first 15 days of the therapy, levetiracetam was added at the dosage of 250 mg b.i.d. or topiramate at 25 mg o.i.d. Efficacy parameters included number of seizure-free days (SFDs), mean and percent reduction in seizure frequency (in general and by type), and number of seizure-free patients in the first 15 days of treatment compared to last 15 days of the baseline period.
Sixty-one patients received levetiracetam and 61 topiramate. The general characteristics of the two treatment groups were similar. The total number of SFDs during
Introduction
Epilepsy is one of the most common neurological disorders, affecting up to 1% of the worldwide population. 1 Despite the large number of antiepileptic drugs available, about 30% of patients still have uncontrolled epilepsy. 2 Levetiracetam is a novel antiepileptic drug with a unique preclinical profile, 3 a favourable pharmacokinetic profile 4 but an as yet unclear mechanism of action, 5 although a brain-binding site in synaptic vesicle protein SV2A has been recently proposed. 6 Levetiracetam has a high therapeutic index and a fairly wide safety margin compared with other antiepileptic drugs. 7 Results from phase II clinical trials evaluating levetiracetam as add-on therapy in patients with refractory partial and/or secondary generalized seizures demonstrated that doses up to 4000 mg/day are effective and well tolerated. 8, 9 The efficacy and tolerability of levetiracetam were confirmed in phase III placebo-controlled studies, in which patients with refractory partial epilepsy received the drug at doses of 1000, 2000, or 3000 mg/day as adjunctive or single treatment. [10] [11] [12] Analysis of pooled data showed a significant gain in seizurefree days (SFDs) in patients on levetiracetam compared to placebo. 13 Both titration and study periods were included in the analysis. In preclinical studies a significant reduction in weekly seizure frequency was observed over the first 2 weeks of the titration period in patients taking levetiracetam, suggesting a fast clinical effect of the drug since the initial dose. 12, 14 Further investigation on the rapid onset of action during the titration phase in three clinical trials showed levetiracetam (1000 mg/day) significantly increasing the mean proportion of seizure-free days 1, 2 and 3 days after the first dose intake. 15 We conducted an observational study to investigate the seizure outcome during the first 15 days at the initial dose of the add-on treatment with levetiracetam as compared to topiramate in adult patients affected by refractory partial epilepsy.
Methods

Study design
This was a single centre, prospective, observational, add-on study. The study was conducted in two distinct phases: (a) baseline: 8-week period; (b) study phase: 15-day add-on therapy with levetiracetam or topiramate, each given as part of a separate prospective observational study. As topiramate was available in the market before levetiracetam, all topiramate patients were recruited first. The titration policy was part of the usual management of the two drugs in the centre's clinical practice (see below). Seizure counts were obtained from patients' diaries according to the centre's standard policy.
Levetiracetam was administered at a dose of 250 mg b.i.d., and topiramate 25 mg in single dose (patients taking an enzyme-inducing drug had as first dose of topiramate 50 mg in single dose).
During each phase concomitant antiepileptic drug (AED) regimens remained unchanged; no other medications were allowed during the study.
Patients were seen in three separate occasions: baseline visit (8 weeks before the beginning of treatment), recruitment visit (beginning of treatment), final visit (15 days after the beginning of treatment). A detailed record of seizures and of any adverse events was available for all patients during baseline and study periods.
Study population
Patients aged 16-60 years with refractory partial epilepsy including simple and complex partial seizures with or without secondary generalisation were eligible.
To be selected, patients had to have a mean monthly seizure frequency !3 during the baseline period; their treatment could include up to two other AEDs.
Patients were excluded if they had a progressive neurological disease, severe psychiatric disorder, Evidence for a rapid action of levetiracetam compared to topiramate 113 medical, hepatic or renal disease, or laboratory abnormalities. Pregnant or lactating women were also excluded.
Efficacy and tolerability assessment
Efficacy was assessed by three parameters evaluated in two matched periods: the 15-day treatment phase and the 15-day period before starting add-on treatment:
a) Total number of seizure-free days; b) Mean and percent reduction in seizure frequency, in general and by seizure type; c) Number of seizure-free patients.
A seizure-free day (SFD) was defined as a day without any seizures. Markowitz et al. 16 have argued that this parameter includes both seizure frequency and seizure severity and best reflects the patient's quality of life.
Tolerability was assessed by recording adverse events, physical and neurological examination. with standard deviations (S.D.), in percent or, where indicated, as odds ratios (OR) with 95% confidence intervals (95% CI).
Statistical analysis
The association between seizure freedom and study drug over the 15 days was also assessed using a multivariate analysis model (logistic regression), adjusting for age, sex, age at onset of seizures, epilepsy duration, number of drugs at admission and seizures in the preceding 15 days.
Results
A total of 122 patients (74 women, 48 men) were enrolled; 61 patients in the levetiracetam group and 61 in the topiramate group. Demographic and clinical features did not differ between the two groups ( Table 1 ). All patients had long-lasting epilepsy, had received 2-9 AEDs, and had high seizure frequency at the baseline visit.
SFDs were 637 before treatment and 748 after treatment with levetiracetam (difference 17.4%) and 621 before treatment and 668 after treatment with topiramate (difference 7.6%) (chi-square test, p = 0.26). The mean (S.D.) number of SFDs increased from 10.4 (4.5) to 12.3 (4.1) with levetiracetam and from 10.2 (4.2) to 10.9 (4.4) with topiramate (ANOVA, p = 0.29). During the 15 days before the beginning of the new treatment, the median number of seizure was 4 (range 0-239) in the levetiracetam group and 5 (range 0-182) in the topiramate group (Wilcoxon's signed-rank test, p = 0.38). During the 15-day add-on treatment the median number of seizure was, respectively, 1 (range 0-177) and 3 (range 0-144) (Wilcoxon's signed-rank test, p = 0.01). The cumulative and mean number of seizures varied significantly by type, but, except for secondary generalized seizures, non-significant differences were found when comparing the two treatments within each seizure category (Table 2) .
Twenty-six patients (42.6%) receiving levetiracetam were seizure-free compared to 10 (16.4%) receiving topiramate (chi-square test, p = 0.003). The numbers for partial seizures were 17 (37.8%) versus 6 (15.4%) (chi-square test, p = 0.02) and those for secondary generalized seizures were 8 (50.0%) versus 7 (29.2%) (chi-square test, p = 0.16).
Logistic regression analysis showed that, over the initial 15-day treatment period, treatment with levetiracetam resulted in a larger number of seizure-free patients than treatment with topiramate (OR: 3.6; 95% CI: 1.5-8.8).
Adverse events were reported by nine patients taking levetiracetam (somnolence 3, nervousness 3, nausea 1, insomnia 1, dizziness 1) and in eight patients taking topiramate (dizziness 2, nervousness 2, somnolence 2, paresthesia 1, diplopia 1). In all patients the adverse events were mild and transient and it was not necessary to stop the treatment.
Discussion
The possibility of a rapid onset of action of levetiracetam has been suggested in open-label and placebo-controlled studies, [10] [11] [12] and in the analysis of the pooled data from placebo-controlled studies.
14 Our study confirmed the rapid onset of action of levetiracetam compared to topiramate, as adjunctive therapy in patients with drug resistant partial epilepsy seen in clinical practice.
The results of the study indicate that adjunctive therapy with levetiracetam 500 mg/day appears more effective than topiramate 25 mg/day in pro- We have no explanation of the rapid onset on action of levetiracetam. Even if our study conclusion is that the treatment with levetiracetam could be effective from the starting dose, the study has several limitations:
-the non-randomized, observational study design implies that this can only be an exploratory comparison of the efficacy of the two drugs; the majority of the patients treated with levetiracetam were different from those taking topiramate and the drugs were given in different periods; -the effects of the daily doses used here, which are only the starting doses, may not apply to the maintenance doses of the two drugs and to any other dose changes, as usually done in clinical practice.
Rapid onset of action does not indicate per se long-term levetiracetam superiority.
Levetiracetam and topiramate showed a good tolerability profile in the first 15 days of treatment as adverse events were mild and transient and no patients discontinued the treatment.
In conclusion, our results appear to confirm previous indications of a rapid onset of action of levetiracetam and seem to suggest a first evaluation of the patient at the dose of 500 mg/day before increasing to the minimum optimised dose of 1000 mg/day, as some patients could respond to the starting dose. This could be also relevant in all cases for which a rapid action is required by particularly severe clinical conditions.
